Navigation Links
Too much SP2 protein turns stem cells into 'evil twin' cancer cells

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.

Dr. Jon Horowitz, associate professor of molecular biomedical sciences, and a team of NC State researchers looked at the protein SP2, which regulates the activity of other genes. They knew that elevated amounts of SP2 had been observed in human prostate-cancer patients, and that these levels only increased as the tumors became more dangerous. They then showed that precisely the same thing occurs in mouse skin tumors.

Horowitz and the team decided to look at SP2 as a possible cause of tumor formation in epithelial cell-derived tumors, which comprise about 80 percent of all human tumors; epithelial cells cover the body's internal and external surfaces. They found that overproduction of the SP2 protein in epithelial stem cells stopped them from spawning mature descendants. The affected stem cells, unable to produce mature cells, just kept proliferating, resulting in the formation of tumors.

The researchers' results are published in the Nov. 3 edition of the journal Cancer Research.

"Something happens to normal stem cells that changes the way SP2 is regulated, and it starts being overproduced," Horowitz says. "SP2 basically hijacks the stem cell, and turns it into its evil twin a cancer cell."

Now that the link between tumor formation and SP2 has been shown, Horowitz says, scientists can turn their attention to looking at ways to target the overproduction of this protein. "Our hope is that we can find an 'antidote' to SP2, to restore normal cell proliferation to those cancer stem cells and reverse the process."


Contact: Tracey Peake
North Carolina State University

Page: 1

Related biology news :

1. Elsevier introduces Protein Viewer, bringing science to life
2. LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension
3. Discovery of a mechanism that controls the expression of a protein involved in numerous cancers
4. Biodegradable foam plastic substitute made from milk protein and clay
5. Reaper protein strikes at mitochondria to kill cells
6. New clues to how cancer-related proteins plasmin, thrombin lose inhibition
7. UMMS researchers identify protein associated with sporadic ALS
8. Key difference in how TB bacteria degrade doomed proteins
9. Shifting forms: Penn study shows how variations of same protein affect immune response
10. New look at multitalented protein sheds light on mysteries of HIV
11. Pitt team finds protein that sets the stage for exchanges of DNA code in eggs and sperm
Post Your Comments:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
Breaking Biology Technology: